Blog

RSS Feed
Posted by Michael Wonder on 20 Jun 2022

EFPIA and Vaccines Europe are deeply disappointed about the decision taken by World Trade Organization at the Ministerial Conference to endorse a TRIPS waiver for COVID-19 vaccines

17 June 2022 - Speaking about the waiver, EFPIA Director General, Nathalie Moll said. “The decision is a serious retrograde step ...

Read more →
Posted by Michael Wonder on 29 Oct 2020

European Patent Office rules in favour of Sanofi and Regeneron concerning Praluent (alirocumab)

29 October 2020 - Ruling invalidates Amgen’s European patent claims directed to PCSK9 antibodies relevant to Praluent (alirocumab). ...

Read more →
Posted by Michael Wonder on 07 Nov 2018

AbbVie announces Humira (adalimumab) global patent license with Momenta

6 November 2018 - AbbVie announced today patent license agreements with Momenta over its proposed biosimilar adalimumab product.  ...

Read more →
Posted by Michael Wonder on 11 Oct 2018

Sandoz announces global resolution of biosimilar adalimumab patent disputes, securing patient access

11 October 2018 - Resolution paves way for 2018 launch in key European markets and secures US market entry planned in ...

Read more →
Posted by Michael Wonder on 25 Nov 2017

EU Ombudsman confirms EMA’s correct handling of declared interests

24 November 2017 - Latest decision concludes no maladministration at EMA. ...

Read more →
Posted by Michael Wonder on 07 Aug 2017

Platform for post-authorisation studies registered as EU trade mark

7 August 2017 - ‘EU PAS Register’ includes more than 1,100 observational post-authorisation studies. ...

Read more →